Targeting KRAS Mutant CMS3 Subtype by Metabolic Inhibitors.

[1]  F. Sotgia,et al.  Cancer metabolism: a therapeutic perspective , 2017, Nature Reviews Clinical Oncology.

[2]  T. Jacks,et al.  PKM2, cancer metabolism, and the road ahead , 2016, EMBO reports.

[3]  F. Minutolo,et al.  Anticancer agents interacting with membrane glucose transporters. , 2016, MedChemComm.

[4]  B. Prabhakar,et al.  Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis , 2016, Cell Death Discovery.

[5]  M. Fraga,et al.  Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer , 2016, Oncotarget.

[6]  P. Massion,et al.  Targeting SLC1a5‐mediated glutamine dependence in non‐small cell lung cancer , 2015, International journal of cancer.

[7]  Wenjing Zhou,et al.  Metformin prevents DMH-induced colorectal cancer in diabetic rats by reversing the warburg effect , 2015, Cancer medicine.

[8]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[9]  L. Castagnoli,et al.  Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions , 2015, PloS one.

[10]  A. McCallion,et al.  Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. , 2015, The Journal of clinical investigation.

[11]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[12]  K. Togashi,et al.  Regulation of 18F-FDG Accumulation in Colorectal Cancer Cells with Mutated KRAS , 2014, The Journal of Nuclear Medicine.

[13]  M. Okada,et al.  Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells , 2014, Oncotarget.

[14]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[15]  Carlo Follo,et al.  PTEN regulates plasma membrane expression of glucose transporter 1 and glucose uptake in thyroid cancer cells. , 2014, Journal of molecular endocrinology.

[16]  Li-Ju Chang,et al.  Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. , 2014, Cell reports.

[17]  G. Schley,et al.  The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity* , 2013, The Journal of Biological Chemistry.

[18]  S. Stone-Elander,et al.  [18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models , 2013, EJNMMI Research.

[19]  Jianming Xu,et al.  Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Carla Mattos,et al.  A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.

[21]  Chi V Dang,et al.  Links between metabolism and cancer. , 2012, Genes & development.

[22]  Gerald C. Chu,et al.  Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.

[23]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[24]  Kaori Togashi,et al.  Relationship between 18F-Fluorodeoxyglucose Accumulation and KRAS/BRAF Mutations in Colorectal Cancer , 2012, Clinical Cancer Research.

[25]  Monica Hoyos Flight.  Anticancer drugs: A sweet blow for cancer cells , 2011, Nature Reviews Drug Discovery.

[26]  Larissa V Furtado,et al.  Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer , 2011, Genes, chromosomes & cancer.

[27]  Shuji Ogino,et al.  NRAS Mutations Are Rare in Colorectal Cancer , 2010, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[28]  C. Thompson,et al.  Glutamine addiction: a new therapeutic target in cancer. , 2010, Trends in biochemical sciences.

[29]  J. Mackey,et al.  Metabolic Modulation of Glioblastoma with Dichloroacetate , 2010, Science Translational Medicine.

[30]  J. Ott,et al.  KRAS Mutation and Microsatellite Instability: Two Genetic Markers of Early Tumor Development That Influence the Prognosis of Colorectal Cancer , 2010, Annals of Surgical Oncology.

[31]  R. Deberardinis,et al.  Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer , 2010, Oncogene.

[32]  J. Feliu,et al.  KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis , 2009, PloS one.

[33]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[34]  K. Kinzler,et al.  Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells , 2009, Science.

[35]  M. Minden,et al.  A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death , 2008, Molecular Cancer Therapeutics.

[36]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[37]  M. Krishna,et al.  Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice , 2008, Proceedings of the National Academy of Sciences.

[38]  A. Sav,et al.  Relationship between overexpression of ras p 21 oncoprotein and Kras codon 12 and 13 mutations in Turkish colorectal cancer patients , 2008 .

[39]  S. Chellappan,et al.  Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. , 2007, Cancer letters.

[40]  Dongsheng Tu,et al.  Cetuximab for the treatment of colorectal cancer. , 2007, The New England journal of medicine.

[41]  S. Minoshima,et al.  MutationView/KMcancerDB: A database for cancer gene mutations , 2007, Cancer science.

[42]  M. Fraga,et al.  Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer , 2006, Oncogene.

[43]  G Smith,et al.  The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma , 2005, Gut.

[44]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[45]  M. Stratton,et al.  Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. , 2002, Cancer research.

[46]  P. Leedman,et al.  Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. , 2002, The Biochemical journal.

[47]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[48]  L. Pauling,et al.  Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[49]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[50]  Michael P. Lisanti,et al.  Cancer metabolism: a therapeutic perspective , 2017, Nature Reviews Clinical Oncology.

[51]  G. Perkins,et al.  Finding a Panacea among combination cancer therapies. , 2012, Cancer research.

[52]  S. Galbavy,et al.  Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients. , 2009, Neoplasma.

[53]  Chi V. Dang,et al.  The interplay between MYC and HIF in cancer , 2008, Nature Reviews Cancer.

[54]  Sébastien Bonnet,et al.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. , 2007, Cancer cell.

[55]  F. Bray,et al.  Predicting the future burden of cancer , 2006, Nature Reviews Cancer.